Humacyte (HUMA) Payables (2020 - 2026)

Humacyte (HUMA) has reported Payables for 7 consecutive years, with $4.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 37.29% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $4.2 million, a 37.29% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, up 20.36% from the prior year.
• Payables was $4.2 million for Q2 2026 at Humacyte, down from $5.1 million in the prior quarter.
• Over five years, Payables peaked at $9.6 million in Q3 2025 and troughed at $1.6 million in Q4 2022.
• A 5-year average of $4.5 million and a median of $4.3 million in 2024 frame the typical range for Payables.
• The widest YoY moves for Payables: up 39764.86% in 2022, down 44.17% in 2022.
• Over 5 years, Payables stood at $1.6 million in 2022, then jumped by 306.9% to $6.5 million in 2023, then plunged by 30.82% to $4.5 million in 2024, then increased by 20.36% to $5.4 million in 2025, then fell by 23.08% to $4.2 million in 2026.
• The last three Payables figures came in at $4.2 million (Q2 2026), $5.1 million (Q1 2026), and $5.4 million (Q4 2025), per Business Quant data.